Public Release: 

Predicting the progression of Alzheimer's

BioMed Central

An assessment has been developed which reliably predicts future performance in cognition and activities of daily living for patients with Alzheimer's disease. Researchers writing in BioMed Central's open access journal Alzheimer's Research & Therapy followed 597 patients over 15 years to identify factors associated with slow, intermediate and rapid progression.

Professor Rachelle Doody worked with a team of researchers from Baylor College of Medicine, Texas, US, to carry out the study. She said, "Patients and families frequently ask clinicians to predict expected rates of cognitive and functional decline, and clinicians currently have little basis for making such decisions. We've found that a simple, calculated progression rate at the initial visit gives reliable information regarding performance over time. The slowest progression group also survives longer."

The research team used a wide combination of standardized tests and scales to assess the ability of their method to predict abilities including memory, language, arithmetic and judgment/problem solving as well as the performance of daily skills over time. In addition to potential use in clinical practice, the team's classification methodology may also have research applications. They write, "Currently, parallel group studies count on randomization to yield comparable placebo and treatment groups. Pre-progression rates are not assessed, yet imbalances across the treatment groups in this important variable could obscure or create treatment differences. Future clinical trials may benefit from gathering systematic data regarding individual symptom onset in order to perform a formal estimate of duration and to calculate pre-progression rates".

###

Notes to Editors

1. Predicting progression of Alzheimer's disease
Rachelle S Doody, Valory Pavlik, Paul Massman, Susan D Rountree, Eveleen Darby and Wenyaw Chan
Alzheimer's Research & Therapy (in press)

During embargo, article available here: http://alzres.com/imedia/1320255922271503_article.pdf?random=920808

After the embargo, article available at journal website: http://alzres.com/

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication

2. Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it will publish open access research articles of outstanding quality. Alzheimer's Research & Therapy will publish basic research with a translational focus, as well as clinical trials, and research into drug discovery and development. Although the primary focus is Alzheimer's dementia, the scope will encompass translational research into other neurodegenerative diseases.

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.